Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.
about
Antihypertensive agents for preventing diabetic kidney diseaseInterplay of vitamin D, erythropoiesis, and the renin-angiotensin systemPerspectives on systems biology applications in diabetic kidney diseaseMeasurement of renal function in patients with chronic kidney diseaseAssessing the Validity of Surrogate Outcomes for ESRD: A Meta-AnalysisPresent and future in the treatment of diabetic kidney diseaseMulticentric validation of proteomic biomarkers in urine specific for diabetic nephropathyAcoustic radiation force impulse imaging for noninvasive evaluation of renal parenchyma elasticity: preliminary findingsRenal recoveryEarly change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysisLabel Free Detection of Sensitive Mid-Infrared Biomarkers of Glomerulonephritis in Urine Using Fourier Transform Infrared Spectroscopy.Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD.Associations of dietary fat with albuminuria and kidney dysfunction.Renal protection in diabetes: lessons from ONTARGET.Kidney function, albuminuria, and all-cause mortality in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study.Impact of age and overt proteinuria on outcomes of stage 3 to 5 chronic kidney disease in a referred cohort.The use of targeted biomarkers for chronic kidney disease.Effect of vitamin-D analogue on albuminuria in patients with non-dialysed chronic kidney disease stage 4-5: a retrospective single center study.End organ damage in hypertension.Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study.Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.T/L-type calcium channel blocker reduces the composite ranking of relative risk according to new KDIGO guidelines in patients with chronic kidney diseaseEarly change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset.Changes in albuminuria predict mortality and morbidity in patients with vascular diseaseinitial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial.Albuminuria and racial disparities in the risk for ESRD.Is nocturnal blood pressure reduction the secret to reducing the rate of progression of hypertensive chronic kidney disease?Prospective Swiss cohort study of living-kidney donors: study protocol.Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study.Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes.Short-Term High Fat Intake Does Not Significantly Alter Markers of Renal Function or Inflammation in Young Male Sprague-Dawley Rats.Significance of urinary full-length and ectodomain forms of megalin in patients with type 2 diabetes.The renal transcriptome of db/db mice identifies putative urinary biomarker proteins in patients with type 2 diabetes: a pilot study.Incidence of stroke symptoms among adults with chronic kidney disease: results from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study.Understanding the mechanisms of proteinuria: therapeutic implicationsUrinary matrix metalloproteinase activity in diabetic kidney disease: a potential marker of disease progression.Repeated treatment with bone marrow cell secretory products maintains long-term renoprotection in experimental chronic kidney disease: a placebo-controlled trial.Biomarkers and surrogate endpoints in kidney disease.Rate and determinants of association between advanced retinopathy and chronic kidney disease in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study.Urine podocin:nephrin mRNA ratio (PNR) as a podocyte stress biomarker
P2860
Q24202090-EDAE1C52-0D87-4B02-A668-FA01AFA6D15DQ26822500-457D7003-B03E-49ED-AD65-E1310D178C30Q26823206-EA907FC3-10EE-4BCD-B757-25E524840BCFQ26853698-3B542FD0-0482-4368-9172-9EE4F74857B6Q26863404-73DA861B-7E0D-4892-B6C5-F605A4431EB1Q26864133-888827EB-66AC-4981-BA30-DE13A8E31BECQ28748796-1972A59E-7F7F-41AF-8201-3FD282B1B483Q30452095-022A4254-F691-493D-8CD0-30EA744D0EA5Q33750273-3321D152-1294-4C5B-8084-67EA93517305Q33805412-290FDDCF-071A-410B-9745-DED6E1AA6525Q33870550-A180CD2C-6D04-47F5-8C1F-BC9567305587Q33901914-5E53E4BC-6DA5-4601-B7F9-EE3DE30EC03FQ34119963-143B0037-5BD2-47D6-9BF4-D2DE07D65AF4Q34221460-6F2D9BD0-A400-4907-A41C-D4CD2DD09268Q34238467-D4D3056C-BBDA-4FEF-B572-21F214063A97Q34281450-828A7049-AFB5-423A-BDB1-17D7B6737425Q34346928-40084D1B-A975-400A-9D0C-689675007357Q34408823-EFBFE5A0-715D-4D57-B994-93904E31138AQ34444944-0806EA88-D722-46DB-B1F5-9693E7AF5823Q34483554-5AA2BE68-193D-437E-8584-241123D1C0C4Q34604473-80636933-22D5-47D3-A972-370D7A43AAB8Q34788186-9EBECBDD-BB02-4C92-9A22-97CEF8743486Q35025425-F928BD9D-AD05-4B1E-A173-72124C83D624Q35108899-F088370B-46CD-428F-8CC6-BB8FC423D2B9Q35179914-C08A3BD0-377F-4DC8-BCC5-A8A562F28820Q35210216-BC8A5A36-6295-4706-86DA-BD5176A89AA3Q35400901-E8A3F3DE-C633-40FA-A762-74AF3AC6F0B0Q35529711-37E6818D-400B-4884-982A-850B55F0BC49Q35620125-3A933A49-219D-4B66-A6F1-81561B4BA7F2Q35721420-E79B7DD4-657E-4CDA-9031-21ED85D92273Q35817372-2DA9F2E3-B432-4647-BF05-FAD04C4E4149Q35898292-1C8AFED4-E0F1-4CB8-9089-BB9D2F96D745Q35924547-F4C700B9-CDB5-4963-AD72-64A6F00BBBE9Q35953248-94B0269E-F179-4759-8E87-E05637A18625Q36100123-226B7472-B381-4ADE-956F-9E8CF187286BQ36206158-32F27E8D-FC0C-4365-9DD3-DDB6517CC7CEQ36278420-A1AE78AF-AAE9-4E7A-8633-70636DC1D586Q36284659-6EF7DBD8-5619-42CE-A10B-395E9950C781Q36334589-DCE44F73-DA24-4738-ABBB-D936FE07FEF4Q36389219-720CFA14-1026-4EAD-A902-3F96EC051A3A
P2860
Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Proteinuria as a surrogate out ...... Food and Drug Administration.
@en
Proteinuria as a surrogate out ...... Food and Drug Administration.
@nl
type
label
Proteinuria as a surrogate out ...... Food and Drug Administration.
@en
Proteinuria as a surrogate out ...... Food and Drug Administration.
@nl
prefLabel
Proteinuria as a surrogate out ...... Food and Drug Administration.
@en
Proteinuria as a surrogate out ...... Food and Drug Administration.
@nl
P2093
P1476
Proteinuria as a surrogate out ...... Food and Drug Administration.
@en
P2093
Aaron Friedman
Andrew S Levey
Bertram Kasiske
Daniel Cattran
John Sedor
Katherine Tuttle
Thomas Hostetter
W Greg Miller
P304
P356
10.1053/J.AJKD.2009.04.029
P577
2009-07-03T00:00:00Z